20 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).
Constellation Pharmaceuticals
Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Constellation Pharmaceuticals
Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.
Constellation Pharmaceuticals
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
Constellation Pharmaceuticals
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Constellation Pharmaceuticals
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymp
Constellation Pharmaceuticals
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.
Constellation Pharmaceuticals
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
Constellation Pharmaceuticals
Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor.
Constellation Pharmaceuticals
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.
Constellation Pharmaceuticals
Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
Janssen Pharmaceutica
JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
Incyte